Hyperfine (HYPR) Revenue Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Revenue Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | 13.02% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 9.42% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 7.53% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 13.63% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 13.08% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 5.75% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 95.64% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 7.30% |
| 10 | Hyperfine | 89.43 Mn | 44.66 Mn | 1.98 Mn | 44.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.81% |
| Mar 31, 2026 | 82.64% |
| Dec 31, 2025 | 128.05% |
| Sep 30, 2025 | -5.65% |
| Jun 30, 2025 | -25.75% |
| Mar 31, 2025 | -35.14% |
| Dec 31, 2024 | -13.59% |
| Sep 30, 2024 | 56.35% |
| Jun 30, 2024 | 7.39% |
| Mar 31, 2024 | 25.05% |
| Dec 31, 2023 | 88.62% |
| Sep 30, 2023 | -0.77% |
| Jun 30, 2023 | 120.55% |
| Mar 31, 2023 | 74.62% |
| Dec 31, 2022 | 226.61% |
| Sep 30, 2022 | 532.88% |
| Jun 30, 2022 | 328.21% |
| Mar 31, 2022 | 355.89% |